StageZero Life Sciences Ltd is dedicated to the early detection of cancer and multiple disease states through whole blood. The company's test consists of Aristotle(R), a multi-cancer panel for simultaneously screening for cancers from a single sample of blood. StageZero Life Sciences Ltd, formerly known as GeneNews Ltd., is based in TORONTO, ON.
| Revenue (Most Recent Fiscal Year) | $3.80M |
| Net Income (Most Recent Fiscal Year) | $-11.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 123.55M |
| Free Float | 120.42M |
| Market Capitalization | $0.63M |
| Average Volume (Last 20 Days) | 2258.50 |
| Beta (Past 60 Months) | -0.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |